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Abstract 
 
Purpose: Whether the association between hypnotic and increased mortality risk is created 
by causation or confounding, has been long debated. We examined further the possibility of 
confounding by indication with a comprehensive approach.  
Methods: The National FINRISK Study cohorts of 1997, 2002, and 2007 (25,436 participants 
aged 25–74) were followed up until July 2012. There were 1,822 deaths, and at least one 
gender, baseline age and cohort matched ‘control’ was found for 1,728 ‘cases’ yielding a 
final analytical sample of 3,955 individuals. An index age, equivalent to the age at death of 
their respective cases’ was set for each control. Hypnotic drug purchases were followed 
from the Finnish nationwide register during a 36-month run-up period before the date of 
death/index date. The prevalence and incidence of hypnotic purchases were compared 
between cases and matched controls. In addition, latent developmental trajectories of 
purchases were modelled and their relations with specific and all-cause death risks were 
analysed. 
Results: An increasing difference between cases and controls was observed as regards the 
use of hypnotic drugs. During the last 30 months before the date of death/index date, the 
rate ratio of incident purchases between cases and controls was 2.37 (95% CL, 1.79–3.12) 
among older and 3.61 (95% CL, 2.37–5.89) among younger individuals. The developmental 
trajectories of hypnotic drug purchases were differently and by interpretation plausibly 
associated with specific mortality risks. 
Conclusions: In most cases the association between hypnotics and mortality risk is created 
by symptomatic treatment when death is approaching.  
 
Keywords: hypnotics, benzodiazepines, z-hypnotics, mortality, death causes  
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1. Introduction 
Several studies have suggested that during the last decades insomnia-related symptoms 
have increased among the general population in, for instance, the UK [1], the US [2], 
Norway [3] and Finland [4]. The number of prescriptions for sleep medication has also 
increased in parallel [2, 3]. In the US, the overall increase in benzodiazepine (BZD) 
prescribing trends has taken place although non-benzodiazepine receptor agonists seem to 
have partially replaced BZDs in the treatment of sleep disorders between 1993 and 2010 [5]. 
In line with this, a decrease in the consumption of traditional hypnotics has been observed 
in Finland, but it is, however, mostly explained by a shift to small sub-clinical doses of 
antidepressants and some other new drugs [6]. The epidemiological data on the still 
continuing and perhaps even strengthening trend of insomnia treatment by 
pharmacological agents emphasises the importance of safety issues regarding long-term use 
of sleep medication.  
Already in 1979, the authors of the re-analyses of the first American Cancer Prevention 
Study concluded that both deviant from population mean sleep duration and use of 
hypnotic medication were independently associated with future death [7]. The relative 
predictive risk was higher among younger than older participants, although absolute risk 
was naturally higher among older age groups. Since then a lively debate on the mortality 
risk associated with hypnotic use has taken place. Most studies suggest that hypnotic use 
has an association with increased all-cause and certain specific (eg cancer) mortality risks 
independent from several pertinent adjustments. See for example [8-11]. However, some 
researchers have come to more critical conclusions, see for instance [12-14]. A recent 
review [15] including 37 studies strongly suggests that the use of sleep medication (mainly 
benzodiazepines and their agonists) is associated with an increased risk of mortality. 
Consequently, the discussion has turned more towards the nature of the hypnotics–
mortality association, that is, whether the association is causal or confounding, rather than 
the possible existence of the association. Notably, however, a recent study reported 
decreased mortality associated with the use of zolpidem [16].  
Several difficult methodological problems have precluded the debate from resolving the 
issue. It is clear that users and non-users of hypnotic drugs differ from each other by several 
confounding factors influencing mortality and morbidity. First, different sleep disturbances 
may have synergistic risk effects with other medical conditions. Additionally, hypnotic drugs 
may worsen some consequences of certain sleep disturbances, such as sleep apnoea, and 
thereby increase mortality risk. Mental health conditions, especially depression, are 
associated with insomnia in a reciprocal way. Alcohol use may have serious interactions with 
hypnotics. These are mere examples of confounders, which are often difficult or even 
impossible to control for in statistical models predicting the mortality risk associated with 
hypnotic drug use. However, it has been concluded that the association is greatly reduced 
after adjusting for baseline risk factors like general health, smoking and physical functioning 
[12, 17]. The authors of one study emphasised that “high-risk patients take more hypnotics, 
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and it is this higher risk rather than the hypnotics that contributes to adverse health 
outcomes” [12]. 
In line with this, a recent a Norwegian study [18] examined a previously unstudied 
confounding factor and provided an alternative explanation for the hypnotics–mortality 
association. When the Norwegian population aged 41–80 was observed in 2010, those who 
died during the first 10 months of that year had a 2.3-fold risk to use hypnotic or opioid 
drugs when compared to those who were alive at the end of the year. Of note, as death 
came closer, the death cohort received drugs with an increasing proportion of users, 
culminating in the greatest frequency in the last few months before death [18]. 
Consequently, the authors concluded that “the association between hypnotic availability 
and mortality can be at least partially, and possibly completely, explained by an increase in 
symptomatic treatment of increasing discomfort as death draws near.” We examined that 
possibility more in-depth by analysing the prevalence and incidence of hypnotic purchases 
from several years before death among the death and control cohorts. Furthermore, we 
evaluated trajectories of hypnotic drug use over the three last years before death using 
latent class growth curve analysis. We expected to find different hypnotic use trajectories to 
be differently associated with specific causes of death, which would indicate that different 
underlying courses of illnesses and their symptoms create different trajectories. This would 
explain a general association between the use of hypnotic drugs and mortality risk. 
 
2. Methods 
 
2.1 Selection of the study population 
The study population was selected from three independent cross-sectional population 
surveys of the National FINRISK Study (1997, 2002, and 2007). FINRISK is a series of large 
cross-sectional health surveys [19].  It includes an extensive health and lifestyle 
questionnaire and a physical examination. Each FINRISK survey is conducted on a random 
sample drawn from the population register of the study regions according to standardised 
sampling methods [20]. Each FINRISK study has the approval of the relevant ethical 
committee and informed consent from all participants.  
The FINRISK samples of 1997, 2002 and 2007 consisted of 25,436 participants (12,151 men 
and 13,285 women) aged 25–74 and living in five geographic areas in Finland. The final 
analytical sample was comprised in the following way. 1) Selection of cases. The three 
FINRISK samples were followed up until 22 June 2012. According to information from the 
National Register of Causes-of-Death, 1,822 individuals had died by that day. They are 
hereafter referred to as “cases” or “death cohort”. 2) Selection of controls. An attempt was 
made to match each case with two personal controls. The matching criteria were gender, 
age (precision ± 2 years) at baseline health examination (ie, age when participating in the 
FINRISK survey) and the FINRISK survey itself (ie, both cases and their controls participated 
in the same FINRISK survey).  
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During the on average 7.6-year follow-up, 1,822 deaths were observed. At least one 
matched control was found for 1,728 (94.8%) individuals. In the 1997 FINRISK survey, among 
the oldest death cases (died at age 65–88) there were 415 individuals who only had one 
living control left. However, for cases who had died during working age (at age 26–64 years) 
two matched controls were always found. We analysed older cases with one matched 
control and younger cases with two matched controls. Consequently, at baseline (time of 
the FINRISK health examination) the final analytical sample consisted of 1,497 younger 
individuals (499 future younger death cases and their 998 personal controls) and 2,458 older 
individuals (1,229 future older death cases and their 1,229 personal controls). Consequently, 
the final analytical sample consisted of 3,955 individuals.  
 
2.2 Analysis period 
As the first step, personal index ages equivalent to the age at death of respective cases was 
set for all controls. For the older group, the median of this age was 74.9 in the 1997 sample, 
73.1 in the 2002 sample and 72.0 in the 2007 sample. For the younger group the ages were 
57.7, 57.2 and 56.6 years respectively. Then, as a second step, a 36-month time period 
(hereafter referred to as a run-up period) before the date of death/index date was defined 
for each individual. Consequently, in the beginning and the end of the run-up period all 
cases were exactly at the same age as their personal controls. The run-up period was then 
divided into 12 three-month time-windows and the participants’ purchases of hypnotic 
drugs were analysed during the three-year run-up period. The width of the time-windows 
was set at three months because Finnish outpatient care only allows drug purchases for no 
more than three months of treatment at one time. 
2.3 Exposure variable: hypnotic (N05C) drug purchases 
The use of hypnotic drugs was assessed by the participants’ reimbursed purchases of 
hypnotic prescription drugs (ATC code N05C) based on the drug purchase register 
maintained by the Finnish Social Insurance Institution Kela, which includes purchases of all 
reimbursed prescription drugs in Finland. Data were obtained from 1 January 1994 to 30 
June 2012. The data include the purchase date, drug substance, amount delivered in defined 
daily doses (DDDs) and a person identification number for each purchase. Purchased drugs 
are coded according to the World Health Organization’s Anatomical Therapeutic Chemical 
(ATC) -classification system [21].  
 
2.4 Background variables 
Register based data were also obtained on purchases of antidepressants (N06A), anxiolytics 
(N05B) and antipsychotics (N05A) during the year of the FINRISK health examination. These 
data were used as background variables. 
The FINRISK surveys provided the following background variables based on either 
questionnaires or health examinations: 1) Socioeconomic characteristics: civil status; 
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education level; household income before taxes. 2) Somatic health status and health risks: 
diagnosed or treated myocardial infarction, hypertension, cancer or diabetes; self-reported 
health; smoking; alcohol use. 3) Mental health status: depression for at least two weeks; 
insomnia-related symptoms; self-reported use of hypnotics, antidepressants and anxiolytics. 
2.5 Outcomes 
In addition to data on the date of death from the national Population Register System (until 
June 2012), specific causes of death were obtained until 31 December 2010 by collating the 
personal identity codes with the death certificate files of Statistics Finland. This yielded a 
definition of a specific cause of death for 1,782 deaths (82% of all deaths). The 
determination of the cause of death was based on medical or forensic evidence, which 
provide the grounds for issuing the death certificate. The causes of death were coded at 
Statistics Finland according to the codes of the International Classification of Diseases (ICD-
10). 
 
3. Statistical methods 
For identification of matched personal controls, a SAS macro Gmatch using the Greedy 
algorithm was applied. Differences between cases and controls across the descriptive 
baseline characteristics were tested by a chi-square test in the case of categorical variables 
and by Anova (SAS proc glm) in the case of continuous variables. The number of new 
incident purchases during the whole 30-month run-up period preceding the date of 
death/index date were modelled using a conditional Poisson regression (SAS proc Genmod). 
The probability of a new incident purchase was modelled separately for each three-month 
time window using logistic regression (SAS proc Genmod). All programming was carried out 
with SAS Release 9.4. 
A variable oriented approach (the above-mentioned conventional analysis of cumulative 
prevalence and incidence) does not take into account that neither cases nor controls are 
homogenous groups in their drug purchase behaviour. Threfore, we also evaluated 
trajectories of hypnotic purchases (yes/no within each consecutive three-month time 
window) over the last 30-month run-up period using the latent class growth curve analysis 
(LCGM) [22]. The LCGM is a semiparametric analysis, which differentiates groups of 
individuals based on their probability of following a similar trajectory on their drug 
purchasing behaviour. We used the SAS procedure Proc Traj [23, 24] where the 
heterogeneity of individual differences in change of outcome is summarised by a set of 
polynomial functions corresponding each to a discrete trajectory. A set of model parameters 
(i.e., intercept and slope) is estimated for each trajectory, so that magnitude and direction 
of change can vary freely across trajectories. In a resulting model, the slope and the 
intercept are fixed across individuals within a given trajectory. In other words, individual 
differences are modelled by the multiple trajectories included in the model. Detailed rules 
of model selection, underlying statistical theory, used software and its functional 
capabilities are available elsewhere [23, 24]. Our aim was to identify possible clusters of 
individuals following similar drug purchase behaviour (developmental drug purchase 
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trajectories) and possible differences between cases and controls. The dependent variable 
used was a dichotomised variable indicating within each three-month time-window whether 
an individual had at least one purchase of hypnotic drugs. Consequently, a series of 12 time 
points during a three-year run-up period was modelled. 
 
 
4. Results 
 
4.1 Descriptive characteristics of selected participants 
 
Descriptive baseline characteristics and a comparison of the selected participants (cases and 
controls) stratified into two age groups are shown in Table 1. Cases and controls differed 
from each other as expected. Among other things, self-reported baseline use of hypnotics 
and the number of insomnia-related symptoms were higher and self-reported health was 
worse in cases than controls. 
 
 Younger group (age at 
death/index age: 26–64) 
Older group (age at death/index 
age:  65–88) 
 Cases 
n=499 
Controls 
n=998 
P 
 
Cases 
n=1229 
Controls 
n=1229 
P 
 
Age (years) at death (cases) and accordingly set 
index age (controls),  mean ± SD 
55.8 ± 7.7 55.8 ± 7.7 1.000 74.6 ± 5.4 74.6 ± 5.4 1.000 
Matched  characteristics       
Men, n (%) 345 (69.1) 690 (69.1) 1.000 821 (66.8) 821 (66.8) 1.000 
Women, n (%) 154 (30.9) 308 (30.9)  408 (33.2) 408 (33.2)  
Age (years) at baseline, mean ± SD 49.7 ± 8.5 49.7 ± 8.5 0.997 66.4 ± 5.1 66.3 ± 5.1 0.692 
Socioeconomic characteristics       
Civil status  Lives alone, n (%) 203 (40.7) 242 (24.3) <.0001 431 (35.1) 338 (27.5) <.0001 
Education level  Basic, n (%) 233 (47.2) 386 (38.7) 0.006 834 (68.9) 755 (62.0) 0.0005 
Education level  Secondary, n (%) 212 (42.9) 485 (48.6)  301 (24.9) 351 (28.8)  
Education level  Higher, n (%) 49 (9.9) 127 (12.7)  75 (6.2) 112 (9.2)  
Household income before taxes       
Low ≤ 16, 820 euros/year, n (%) 162 (33.5) 161 (16.5) <.0001 530 (46.3) 415 (34.8) <.0001 
Intermediate 16,821 – 42,051 euros/year, n 
(%) 
219 (45.3) 459 (47.0)  483 (42.2) 562 (47.2)  
High ≥ 42,051 euros/year, n (%) 103 (21.3) 357 (36.5)  133 (11.6) 215 (18.0)  
Somatic health status and health risks at 
baseline 
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Diagnosed  myocardial infarction  Yes, n (%) 29 (5.9) 15 (1.5) <.0001 166 (15.2) 101 (8.5) <.0001 
Diagnosed or treated hypertension  Yes, n (%) 154 (31.1) 284 (28.7) 0.334 541 (45.1) 477 (39.1) 0.003 
Diagnosed or treated cancer  Yes, n (%) 26 (5.4) 8 (0.8) <.0001 63 (5.8) 47 (4.0) 0.047 
Diagnosed or treated  diabetes  Yes, n (%) 51 (10.5) 46 (4.7) <.0001 176 (16.3) 107 (9.2) <.0001 
Self-reported health  Fairly or very bad, n (%) 114 (23.1) 99 (10.0) <.0001 254 (23.1) 122 (10.3) <.0001 
Body mass index, mean ± SD 27.6 ± 5.4 27.5 ± 4.5 0.564 28.3 ± 4.9 27.9 ±4.0 0.042 
Smoking  Smoke currently n (%) 251 (50.5) 267 (26.9) <.0001 303 (27.7) 118 (10.0) <.0001 
Alcohol  Intoxicated no more than twice per 
month n (%) 
216 (44.6) 503 (51.8) 0.0005 401 (37.1) 425 (37.0) 0.115 
Alcohol  Intoxicated more often n (%) 158 (32.6) 224 (23.1)  115 (10.7) 94 (8.2)  
Mental health status, sleep, use of 
psycholeptic (N05) and antidepressant (N06A) 
drugs at baseline 
      
Depression for at least two weeks  Yes, n (%) 160 (32.4) 205 (20.7) <.0001 245 (20.9) 187 (15.5) 0.0007 
Self-reported use of antidepressants 
During last month or earlier n (%) 
83 (17.3) 103 (10.5) 0.0002 142 (13.4) 111 (9.5) 0.004 
Register based purchases of antidepressants 
(N06A) At least one purchase during the 
baseline year 
66 (13.2) 69 (6.9) <.0001 127 (10.3) 83 (6.8) 0.002 
Insomnia-related symptoms During last month: 
occasionally or often 
263 (54.0) 456 (46.4) 0.006 606 (52.8) 591 (49.2) 0.083 
Self-reported use of hypnotics  During last 
month 
n (%) 
72 (14.9) 66 (6.7) <.0001 193 (18.1) 157 (13.4) 0.004 
Self-reported use of hypnotics  1-12 months 
ago or earlier n (%) 
101 (21.0) 119 (12.1)  166 (15.6) 166 (14.2)  
Register based purchases of hypnotics (N05C) 
At least one purchase during the baseline year 
n (%) 
74 (14.8) 61 (6.1) <.0001 232 (18.9) 139 (11.3) <.0001 
Self-reported use of anxiolytics  During last 
month n (%) 
60 (12.4) 44 (4.5) <.0001 98 (9.3) 79 (6.8) 0.080 
Self-reported use of anxiolytics 1-12 months 
ago or earlier n (%) 
67 (13.8) 85 (8.7)  125 (11.8) 131 (11.2)  
Register based purchases of anxiolytics (N05B) 
At least one purchase during the baseline year 
n (%) 
75 (15.0) 43 (4.3) <.0001 138 (11.2) 114 (9.3) 0.111 
Register based purchases of antipsychotics 
(N05A) At least one purchase during the 
baseline year n (%) 
38 (7.6) 18 (1.8) <.0001 91 (7.4) 32 (2.6) <.0001 
 
Table 1. Descriptive characteristics of selected participants included in the study by age 
groups at baseline in the National Finrisk Study cohorts of 1997, 2002, and 2007 
 
4.2 Purchases of hypnotic (N05C) drugs 
 
4.2.1 Initial prevalence 
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The prevalence of hypnotic (N05C) purchases differed significantly between cases and 
controls during the three-year run-up time before the date of death/index date. The run-up 
period was divided into 12 time-windows, three-months each. We considered that the first 
two time-windows (months 36–31 before the date of death/index date) would reveal 
current hypnotic users at that time. The initial six months prevalence figures were 3.7% 
among younger controls, and 8.0% among older controls. The corresponding figures were 
11.4%, and 16.2% among cases, respectively. (See also Table 2).  
 
4.2.2 Cumulative incidence after the initial 6 months phase of the run-up period 
After the initial six-month period (months 30–1 before the end of the run-up period), 
cumulative incidence was calculated for each three-month time-window and a rate ratio in 
each time-window was calculated between cases and controls in both age groups. The 
resulting 30-month cumulative incidence of new buyers was 4.3% among younger controls, 
and 6.9% among older controls. The corresponding figures were 14.4%, and 14.8% among 
cases, respectively. (See also Table 2.) A graphical illustration for the older age group is 
shown in Figure 1. Across the whole 30-month period, the rate ratio estimate of incident 
purchases between cases and controls among the older study group was 2.37 (95%CL 1.79–
3.12), and among the younger study group 3.61 (95%CL 2.37–5.89). The number of new 
incident users was analysed with pertinent explanatory variables using multivariable 
conditional Poisson regression with robust error variance (Table 2). 
 
[Figure 1 about here; single column; in colour] 
Figure 1. Cumulative incidence of new buyers of hypnotic drugs among the older age group 
during the last 30-months preceding the date of death/index date 
Especially during the last three months before the date of death/index date, the increase in 
rate ratio among the older age group was remarkable (Figure 2), which indicates that the 
incidence rate of new buyers was several times higher among cases than controls. However, 
among the younger subgroup, only few incident cases were revealed within each separate 
three-month time-window and, consequently, confidence intervals for separate estimates 
were too large to infer anything about the possible time trend of rate ratio estimates in the 
younger study group. 
 
[Figure 2 about here; single column, balck and white] 
 
Figure 2. Rate ratio estimates of new incident buyers for each time-window during the last 
30 months between cases and controls among the older study group  
The results of multivariable conditional Poisson regression models are shown in Table 2. 
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Models Initial 6 months prevalence of N05C purchases 30 months cumulative incidence of new buyers 
Younger study group 
(age at death/index age 26–
64) 
Older study group 
(age at death/index age 65–
88)  
Younger study group 
( age at death/index age 26–
64) 
Older study group 
(age at death/index age 65–
88) 
RR  95% CL RR  95% CL RR  95% CL RR  95% CL 
Model I (initial model with condition case/control and gender) 
Case (ref control) 3.10 2.09 - 4.60 1.92 1.54 – 2.40 3.39 2.28 – 5.03 2.37 1.79 – 3.12 
Women (ref men) 1.53 1.04 – 2.25 1.56 1.27 – 1.91 1.37 0.92 – 2.04 1.21 0.92 – 1.58 
Model II = Model I + Sociodemographic factors* 
Case (ref control) 2.96 1.98 – 4.42 1.90 1.52 – 2.39 3.44 2.30 – 5.16 2.34 1.79 – 3.06 
Women (ref men) 1.49 1.01 - 2.20 1.52 1.22 – 1.89 1.37 0.93 – 2.01 1.20 0.93 – 1.57 
Model III = Model I + Somatic health factors at baseline** 
Case (ref control) 2.41 1.47 – 3.98 1.50 1.16 – 1.95 2.98 1.95 – 4.56 2.33 1.72 – 3.15 
Women (ref men) 1.82 1.17 - 2.84 1.76 1.32 – 2.35 1.40 0.91 – 2.17 1.62 1.20 – 2.21 
Self/reported health bad 
(ref very or fairly good) 
2.18 1.37 – 3.46 1.70 1.30 – 2.21 1.05 0.50 – 1.56 1.36 0.98 – 1.89 
Cancer yes (ref no) 0.28 0.04 – 2.15 1.51 1.00 – 2.27 2.04 1.00 – 4.17 1.46 0.91 – 2.33 
Hypertension yes (ref no) 1.37 0.88 – 2.12 1.24 0.98 – 1.58 1.27 0.85 – 1.88 1.41 1.07 – 1.84 
Alcohol: drunken at least 2 
times/month 
(ref not once) 
1.08 0.66 – 1.79 1.34 0.85 – 2.09 1.29 0.82 – 2.00 1.84 1.29 – 2.62 
Model IV = Model I + Mental health factors at baseline*** 
Case (ref control) 2.20 1.51 – 3.20 1.76 1.43 – 2.17 2.91 1.96 – 4.32 2.30 1.76 – 3.00 
Women (ref men) 1.19 0.82 – 1.73 1.31 1.08 - 1.60 1.29 0.89 – 1.87 1.14 0.89 – 1.47 
Insomnia symptoms yes (ref no)  4.72 3.26 – 6.83  4.30 3.47 – 5.34 2.63 1.69 – 4.08 1.99 1.44 – 2.74 
Purchases of antidepressants (N06A) 
during baseline year yes (ref no) 
1.92 1.25 – 2.95 1,67 1.29 – 2.18 1.81 1.05 – 3.14 1.29 0.83 – 2.00 
Purchases of anxiolytics (N05B) 
during baseline year yes (ref no) 
2.51 1.63 – 3.87 1.61 1.25 – 2.07 1.50 0.88 – 2.54 1.44 0.97 – 2.15 
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*Sociodemographic factors: Not shown non-significant effects of civil status, education level and household 
income before taxes 
** Somatic health factors at baseline: Not shown non-significant effects of diagnosed myocardial infarction, 
diabetes, body mass index and smoking 
*** Mental health factors at baseline: Not shown non-significant effect of purchases of antipsychotics  
 
Table 2. Multivariable conditional Poisson regression models providing RR estimates 
predicting the initial six months (the 36–31 months before the date of death/index date) 
prevalence of hypnotic purchases and the later 30 months (the following 30–1 months) 
cumulative incidence of new buyers. Statistically significant estimates are shown in bold. 
 
The results of the multivariable conditional Poisson regression models revealed that the RR 
estimates between cases and controls were not substantially attenuated when pertinent 
sociodemographic (Table 2, Model II), somatic (Table 2, Model III) or mental (Table 2, Model 
IV) baseline health factors were accounted for. 
 
4.2.3 Developmental trajectories of N05C purchases 
At first, models with 2, 3, 4 and 5 trajectory groups were fit into the whole analytical study 
sample. The models were compared by the Bayesian information criterion (BIC) and the log 
Bayes factor was calculated when the different numbers of trajectories in nested models 
were tested. These comparisons revealed very strong evidence (the log Bayes factor 
between the models with 4 and 5 trajectories was 143.2) that the model with 5 trajectories 
fitted the data best. The reliability (the average posterior probability of group membership) 
of its trajectories was very good (0.806–0.987). The interpretation of the trajectory groups 
was plausible and although four groups had less than five percent prevalence, it was chosen 
as the best model for the data (Figure 3).  
 
[Figure 3 about here; single column; colour] 
 
Figure 3. The developmental latent trajectories of N05C purchases during the three-year 
run-up period before the date of death/index date. (12 three-month time-windows). 
 
The first trajectory was named “continuously increasing use”. Its prevalence was 3.4%. 
Persons in this group were characterised by a steady linear increase in their hypnotic use 
throughout the whole three-year period. The second trajectory, “non-users”, had a 
prevalence of 84.5%. Characteristic of this group was a continuous lack of hypnotic 
purchases. The third group was named “continuously decreasing use” and had a prevalence 
of 4.7%. This group was characterised by a steady linear decrease in N05C purchases during 
the whole three-year period. The fourth group, ”new users during the end period”, 
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consisted of persons who had very few purchases during the first year but rapidly increasing 
purchases during the last two years. The prevalence of this group was 2.8%. The fifth group 
was named “continuously high use”. Its prevalence was 4.6% and its members were 
characterised by a relatively steady and frequent use of hypnotics. According to the 
maximum-probability assignment rule, each individual was then grouped between the 
trajectories. After that, the distribution of cases and controls between trajectories was 
tested. As expected, the distribution differed statistically significantly (Chi-Square 140.8 
(3955) df=4, p<.0001) (Table 3). 
 
Trajectory group Cases Controls All 
n 
1 “Continuously increasing use” 72 (59.5%) 49 (40.5%) 121 
2 “Non-users” 1348 (39.9%) 2032 (60.1%) 3,380 
3 “New users during the end period” 119 (69.2%) 53 (30.8%) 172 
4 “Continuously decreasing use” 67 (70.5%) 28 (29.5%) 95 
5 “Continuously high use” 122 (65.2%) 65 (34.8%) 187 
All  1,728 (43.7%) 2,227 (56.3%) 3,955 
 
Table 3. Distribution of cases and controls across five drug use trajectory groups 
 
The prevalence of cases (in other words the death risk) was approximately 2.1–3.5-fold in 
different user trajectory groups when compared with non-users. To test whether user 
groups differed from each other as regards the case–control distribution, gender and age 
adjusted relative risk (RR) estimates of being a case vs a control were calculated using the 
“non-users” group as reference. The relative risk of all-cause mortality was found to not 
differ statistically significantly between trajectory groups 1, 3, 4 and 5. See Table 4.   
 
Trajectory group RR 95% Confidence limits 
2 “Non-users” ref  
1 “Continuously increasing use”  2.1 1.45 – 3.05 
3 “New users during the end period” 3.49 2.23 – 5.46 
4 “Continuously decreasing use” 3.36 2.41 – 4.70 
5 “Continuously high use” 2.66 1.95 – 3.62 
 
Table 4. Relative risk (RR) estimates of deaths adjusted for gender and age by trajectory 
groups using “non-users” as reference 
 
However, different developmental hypnotic drug use trajectories reflected different 
underlying medical conditions. The distribution of baseline medical conditions across 
trajectory groups is shown in Table 5. 
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Baseline 
medical 
condition 
Trajectory 2 
Non-users 
Trajectory 1 
Continuously 
increasing use 
Trajectory 3 
New users 
during the 
end period 
Trajectory 4 
Continuously 
decreasing use 
Trajectory 5 
Continuously 
high use 
Chi-square 
P 
Myocardial 
infarction 
8.3% 7.7% 14.8% 9.2% 14.1% 0.007 
Hypertension 35.5% 29.0% 40.0% 35.2% 45.1% <.0001 
Cancer 3.5% 9.4% 5.6% 5.5% 4.7% 0.017 
Depression 4.2% 14.7% 7.1% 11.9% 14.3% <.0001 
 
Table 5. Distribution of baseline illnesses within 5 drug use trajectory groups 
 
The baseline conditions of cardiovascular diseases (myocardial infarction and hypertension) 
were associated with future hypnotic use trajectories 3 (new users during the end period) 
and 5 (continuously high use). Highest cancer prevalence was found among trajectory 1 
(continuously increasing use) and highest prevalence of depressive symptoms among 
trajectories 1 (continuously increasing use), 5 (continuously high use), and 4 (continuously 
decreasing use). 
In addition, and more importantly, specific causes of death characterised different 
developmental hypnotic drug use trajectories. Table 6 shows statistically significant RR 
estimates of specific causes of death (1,417 cases) using the non-users group as a reference 
group.   
 
Death cause: ICD-10 codes Trajectory 1 
Continuously 
increasing 
use  
Trajectory 
3 
New users 
during the 
end period 
Trajectory 4 
Continuously 
decreasing 
use  
Trajectory 5 
Continuously 
high use  
Malignant neoplasms (cancer): C00–C97 1.6 
(0.028) 
3.5 
(<.0001) 
  
Degenerative diseases of the nervous system 
(dementia, Alzheimer): F00–F09; G30 
  3.4 
(0.002) 
 
Hypertensive diseases: I10–I15 4.5 
(0.050) 
   
Ischaemic heart diseases: I20–I28    1.8 
(0.002) 
Pneumonia: J00–J99 3.0 
(0.012) 
  2.6 
(0.013) 
Diseases of the liver: K70–K77   5.3 
(0.003) 
 
External causes of accidental injury, excluding 
transport accidents: W00–X59; Y00–Y34 
  2.2 
(0.034) 
 
Intentional self-harm (suicide): X60–X84  7.6 
(<0.001) 
  
 
Table 6. Relative risk (RR) estimates of specific causes of death in different developmental 
hypnotic drug use trajectories (non-users as reference) adjusted for gender and age. 
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When compared with the trajectory group 2 (non-users), continuously high use of hypnotics 
(trajectory group 5) was associated with increased risk of death caused by ischemic heart 
diseases and pneumonia. Continuously increasing use of hypnotics (trajectory 1) was 
associated with increased risk of death caused by cancer (mostly breast cancer), 
hypertensive disease, and pneumonia. Trajectory group 3, characterised by a rapidly 
increasing number of new individuals making purchases during the end period, was 
associated with increased risk of death caused by cancer and suicide. Continuously 
decreasing purchases of hypnotics (trajectory 4) were associated with increased risk of 
death caused by degenerative diseases of the nervous system, diseases of the liver and 
external accidental injury excluding transport accidents. See Table 6. 
 
5. Discussion 
Our main results indicate that the use of hypnotic drugs was associated with future death in 
several ways. 1) In the baseline health examination (5–15 years before the end of the 
follow-up), the proportion of hypnotic users was significantly higher among members of the 
death cohort, or cases, than among controls. The death cohort also had more insomnia-
related symptoms and worse self-reported health. 2) This difference between cases and 
controls increased when death approached, and resulted in a two to three times higher 
prevalence of hypnotic users during months 36–31 before the date of death/index date 
among members of the death cohort than among controls. 3) During the last 30-month run-
up period, the cumulative incidence of new users was also two to three times higher among 
cases than controls. 4) The difference in incidence rate of new users increased steeply 
between older cases and controls during the last three months. 5) During the 36-month run-
up period before the date of death/index date, we found five different developmental drug 
purchase trajectories, four of which were associated with increased risk of death when 
compared with the non-users reference trajectory. 6) Different specific causes of death 
characterised different developmental hypnotic drug use trajectories. 
 
5.1 The role of follow-up time length and age 
The length of the follow-up time in previous studies has varied greatly in association with 
mortality risk estimates. The association of hypnotic drug use with mortality has been 
generally stronger in studies with shorter follow-up time lengths than in longer studies [15]. 
In previous follow-up studies, one of the shortest time lapses between any hypnotic drug 
exposure (mean eight pills/year) and prospective death risk was an average of 2.5 years’ 
follow-up [8] giving also one of the highest risk estimates (3.6 times higher hazard of dying). 
Based on previous studies, it has been inferred that the greatest hazard is associated with 
initial drug doses [25]. However, at the same time deaths during the first year after baseline 
are often excluded, resulting in an emphasis of “the hypnotic survivors rather than the high 
initial risk” [25].  
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In our study, we found that both self-reported and reimbursement-based register data 
indicated higher prevalence of hypnotic users among the death cohort than among their 
age, gender and health examination date matched controls already in the beginning of an 
average of 7.6-year follow-up period. Among younger participants, the self-reported 
difference was 2.2-fold and the register-based difference 2.4-fold, among older participants 
the differences were 1.3-fold and 1.7-fold, respectively.  This is similar to how the hypnotic–
mortality risk association has usually shown in previous studies. It has been suggested that 
the association arises early in the period of drug use and continues to exist even after 
hypnotics are discontinued [9]. We found that the difference in the initial baseline 
prevalence of hypnotic users between cases and controls increased further during the 
follow-up period and was two to three-fold during the first six months in the beginning of 
the three-year run-up period before the date of death/index date. Overall, during the 2.5-
year run-up period before the date of death/index date, the cumulative incidence of new 
purchases among cases was also two to three times that of controls. Among older 
participants, that difference in cumulative incidence increased extremely steeply during the 
final three months before the date of death/index date. That was preceded by a sharp dip in 
the difference between cases and controls six to four months before the date of 
death/index date. Our interpretation of this dip is that this point, among cases, approaching 
death causes several institutionalisations or hospitalisations. Therefore, the future use of 
hypnotics among these individuals was no longer reflected in the drug purchase register, 
which only covers outpatient care. Because there were only few new incident cases among 
younger individuals within each three-month time-window, we were unable to statistically 
confirm the dynamics of cumulative incidence in younger participants. Therefore, it is 
difficult to conclude whether our results on cumulative incidence of hypnotic purchases 
corroborate the suggestion that the hypnotic–mortality association is more easily seen 
among younger than older adults [17]. However, the difference between cases and controls 
in overall 30-month cumulative incidence was somewhat greater among younger than older 
individuals. These results are in line with analogous recent findings, where during a 24-
month run-up period before the date of death/index date the prevalence of hypnotic users 
increased as death neared in the death cohort but not among the control group, and the 
greatest difference was found in the younger age group [18].  
The previously reported influence of follow-up time length on mortality estimates probably 
reflects differences in the development of individual drug use histories or trajectories 
among cases and controls in time. It is clear that hypnotic users are not a homogeneous 
group. As regards their hypnotic use behaviour in time, they form a mixture of different 
subgroups. It has been stressed [15] that in studies with long follow-up periods predicting 
mortality risk with baseline drug use, participants who used hypnotics at baseline may not 
necessarily continue their use over the whole follow-up period. In addition, control 
participants may start to use hypnotics after the baseline assessment. Consequently, “the 
actual hypnotic consumption of the control group would more and more approximate that 
of the baseline hypnotic users” [15]. The person-oriented analysis, modelling individual 
developmental hypnotic use trajectories, can therefore importantly increase our 
understanding of the underlying mechanisms behind the hypnotic–mortality association.  
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5.2 Developmental drug use trajectories and specific mortality causes 
To our best knowledge, all previous studies have used a conventional variable oriented 
approach in their analyses. We analysed a three-year run-up period before the date of 
death/index date among all participants using a person-oriented approach the latent class 
growth curve analysis and found five different developmental drug purchase trajectories, 
four of which were associated with increased risk of death when compared with the non-
users’, reference trajectory. Taken together, relative risk estimates were statistically of the 
same size between risk groups and varied between 2.10 and 3.49.  
Upon discussing “the use of hypnotics and prospective mortality risk”, an important 
question has been whether hypnotics are associated with specific causes of death. Several 
previous studies have lacked data on the causes of death. Studies including this information 
have suggested that the use of hypnotics may be associated with some specific causes of 
death, such as suicide [26, 27], coronary artery disease [26], dementia and Alzheimer’s 
disease [28], and cancer [8, 11]. In our study, an important and new finding was that 
different developmental trajectories of hypnotic drug use were differently associated with 
specific (including the above-mentioned) causes of death. When compared with “non-
users”, the trajectory “continuously increasing purchases” was associated with increased 
risk of death by cancer (mainly by breast cancer), hypertensive diseases and pneumonia. 
The trajectory “new purchases during the end period” was associated with increased risk of 
death caused by cancer and suicides. The trajectory “continuously decreasing purchases” 
was associated with increased risk of death caused by degenerative diseases of the nervous 
system (dementia, Alzheimer’s disease), diseases of the liver and external causes of 
accidental injury except transport accidents. Finally, the trajectory “continuously high use” 
was associated with increased risk of death caused by ischaemic heart diseases and 
pneumonia. In general, these results clearly support the assumption of reverse causation or 
confounding by indication, as has been recently suggested [18].  
The wide range of different causes of death, associated with the use of hypnotics, suggest 
that there is no specific single mechanism behind the hypnotic–mortality risk association. 
There are most probably several underlying mechanisms creating the association. It has 
been emphasised that most patients who are prescribed hypnotics are multimorbid [29]. 
Purchase register data does not reveal why hypnotics are bought. However, it is plausible 
that sleeping problems and discomfort related to specific diseases like degenerative 
diseases of the nervous system and/or multimorbidity are often behind the prescription of 
hypnotics, although a clear-cut indication may be lacking [29]. Indirectly, the assumption is 
also supported by the recent finding that in most cases when physicians prescribe hypnotics 
they record no indication of insomnia or another medical reason for the prescription [15]. 
Against this background, our trajectories are interpreted as follows. Either those with 
“continuously increasing purchases” are increasing the frequency of their drug purchases or 
the group is gaining new incident users. It is plausible that this kind of behaviour is 
associated with increased symptomatic treatment of discomforts caused by approaching 
death by (breast) cancer, hypertensive diseases and pneumonia.  
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Among the group of “new purchases during the end period” new incident cases of hypnotic 
users accumulate rapidly during the last 1.5 years before the date of death/index date 
although there were very few purchases before that. This kind of behaviour is plausibly 
explained by symptomatic treatment of rapidly worsening (mental) health problems leading 
to suicide as well as symptomatic treatment of discomfort caused by rapidly progressive 
cancer.  
Within the frame of continuous purchases, there is a linear trend of discontinuation of drug 
purchases when the date of death/index date is approaching among members of the 
trajectory group “continuously decreasing purchases”. A plausible explanation is that 
degenerative diseases of the nervous system (dementia, Alzheimer’s disease), diseases of 
the liver and external causes accidental injuries caused the hospitalisation or 
institutionalisation of these patients and therefore their drug use is no longer reflected in 
the reimbursement register, which only covers outpatient treatment. However, deaths 
caused by external causes of accidental injury, excluding transport accidents, may also be 
related to hangover effects, such as daytime sedation, reduced vigilance and psychomotor 
impairment caused by the hypnotics themselves [30-32]. The discontinuation of drug 
purchases could theoretically also be interpreted as a sign of remission. This is, however, 
not believable because the trajectory was associated with increased mortality risk. Finally, 
the high frequency of hypnotic purchases among the members of the trajectory group 
“continuously high use” is plausibly explained by symptomatic treatment of discomfort 
caused by ischaemic heart diseases. Altogether we feel that the finding of specific causes of 
death associated with different specific drug use trajectories in time strongly supports the 
interpretation of the hypnotics-mortality association being, at least in most cases, caused by 
confounding by indication as Neutel and Johansen have suggested [18]. 
5.3 Strengths and limitations of the study 
Our study has several strengths when compared with many earlier studies. First, we used 
register databases to identify hypnotic drug purchases without any loss in follow-up and 
specific causes of death. According to the annual wholesale statistical database compiled by 
the Finnish Medicines Agency FIMEA, from 1 January 2006 to 31 December 2010 the 
purchase register of the Finnish Social Insurance Institution Kela included data on 81% of the 
total outpatient consumption of hypnotic (N05C) drugs giving a relatively strong confidence 
on our estimate of hypnotic drug use [6].  Based on a health examination and 
questionnaires in the beginning of the follow-up we had information on background 
characteristics regarding the individuals’ health status, drug use, life style factors and 
socioeconomic status. We were able to define the exposure to hypnotic drugs. Furthermore, 
our prevalence models were adjusted for register-based use of antidepressants, anxiolytics 
and antipsychotics confirming that they did not explain the difference in hypnotics between 
cases and controls. An important strength is that, according to our best knowledge, our 
study adds a new, person-oriented analysis to previous studies. Latent trajectory groups 
provided an opportunity to model different drug purchase patterns in time without fixed a 
priori assumptions about their number and nature. Consequently, different types of timing 
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of exposure during the three-year run-up period before the date of death/index date could 
be revealed.  
However, our study also has some limitations, which should be taken into account when 
considering its results. Irrespective of the strengths of our register-based estimate of 
hypnotic drug use, it also has some uncertainties. It is somewhat uncertain how accurately 
register-based purchases reflect the actual usage of hypnotics. We did not analyse the 
amount or doses actually used, only the frequency of registered purchases. It is important, 
however, to note that actually used doses of hypnotics are impossible to estimate reliably 
based on purchase data. Hypnotics are drugs used “when needed”, which make them 
significantly different from, for instance, antibiotics or antihypertensive drugs, which are 
prescribed with specific daily doses to be used.  
5.4 Conclusion 
Although our data does not prove inferences on directions of causality behind the 
association of hypnotic use and increased mortality, it describes how the association is 
shaped by different drug use patterns in time in a more detailed way than previous studies. 
Taken together, these results give further evidence suggesting that in most cases, except 
perhaps some accidental injuries, the association is created without specific biological 
mechanisms by symptomatic treatment of discomfort caused by terminal illnesses. This 
conclusion is reassuring for patients and doctors in everyday clinical practice. It does not, 
however, mean that generally accepted guidelines to limit the use of hypnotics to the short-
term use only and to increase nonpharmacological treatment in line should not be 
continued.  
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Association of hypnotic drugs with mortality is shaped by different drug use patterns 
Different hypnotic drug use trajectories reflect different specific causes of death   
Underlying mechanism is probably symptomatic treatment of terminal illnesses 
